Recombinant Mycobacterium bovis BCG is a promising platform to develop vaccines against Trypansoma cruzi infection. 2020

I Bontempi, and K Leal, and E Prochetto, and G Díaz, and G Cabrera, and A Bortolotti, and H R Morbidoni, and S Borsuk, and O Dellagostin, and I Marcipar
Facultad de Bioquímica y Ciencias Biológicas, Universidad Nacional del Litoral, Santa Fe, Argentina.

Chagas disease, caused by the hemoflagelate parasite Trypanosoma cruzi, is one of the most prevalent endemic parasitoses, affecting 7-8 million people. Due to the complexity of the infection, no vaccines are available at present. The extraordinary adjuvant capacity of bacille Calmette-Guérin (BCG) was explored in this work to develop a vaccine candidate to protect against T. cruzi infection using the recombinant BCG (rBCG) vaccine platform. Three antigens of the parasite corresponding to the N and C terminal fragments of the enzyme trans-sialidase (NT-TS and CT-TS, respectively) and a fragment of the cruzipain enzyme (CZf) were cloned into the vectors pUS997 and pUS2000 and transformed into the BCG Pasteur strain. In vaccinated mice, rBCG expressing NT-TS in pUS2000 plasmid provided the highest protection and the lowest parasitemia after challenging BALB/c mice with a 50% lethal dose of parasites. When mice vaccinated with pUS2000-NT-TS were challenged with a 100% lethal dose of parasite, high levels of protection were also obtained, together with a low degree of cardiac lesions 120 days after infection. In immunized mice with pUS2000-NT-TS/rBCG clone, the proliferation of CD4+ cells from splenocytes stimulated with the TS antigen was significant; this stimulation increased interferon (IFN)-γ and interleukin (IL)-17 within CD4⁺ T lymphocytes (LTCD4+ ) cells and IFN-γ and CD107 expression within LTCD8+ cells. Therefore, pUS2000-NT-TS/rBCG conferred high levels of protection, which correlated with an immune response orientated towards a T helper type 1 (Th1)/Th17 profile, together with an LTC-specific response, indicating that rBCG is a promising platform to develop vaccines against T. cruzi.

UI MeSH Term Description Entries
D007114 Immunization Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow). Immunologic Stimulation,Immunostimulation,Sensitization, Immunologic,Variolation,Immunologic Sensitization,Immunological Stimulation,Sensitization, Immunological,Stimulation, Immunologic,Immunizations,Immunological Sensitization,Immunological Sensitizations,Immunological Stimulations,Sensitizations, Immunological,Stimulation, Immunological,Stimulations, Immunological,Variolations
D009163 Mycobacterium bovis The bovine variety of the tubercle bacillus. It is called also Mycobacterium tuberculosis var. bovis. BCG,Calmette-Guerin Bacillus
D009439 Neuraminidase An enzyme that catalyzes the hydrolysis of alpha-2,3, alpha-2,6-, and alpha-2,8-glycosidic linkages (at a decreasing rate, respectively) of terminal sialic residues in oligosaccharides, glycoproteins, glycolipids, colominic acid, and synthetic substrate. (From Enzyme Nomenclature, 1992) Sialidase,Exo-alpha-Sialidase,N-Acylneuraminate Glycohydrolases,Oligosaccharide Sialidase,Exo alpha Sialidase,Glycohydrolases, N-Acylneuraminate,N Acylneuraminate Glycohydrolases,Sialidase, Oligosaccharide
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003001 Cloning, Molecular The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells. Molecular Cloning
D003546 Cysteine Endopeptidases ENDOPEPTIDASES which have a cysteine involved in the catalytic process. This group of enzymes is inactivated by CYSTEINE PROTEINASE INHIBITORS such as CYSTATINS and SULFHYDRYL REAGENTS.
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

I Bontempi, and K Leal, and E Prochetto, and G Díaz, and G Cabrera, and A Bortolotti, and H R Morbidoni, and S Borsuk, and O Dellagostin, and I Marcipar
November 2009, Vaccine,
I Bontempi, and K Leal, and E Prochetto, and G Díaz, and G Cabrera, and A Bortolotti, and H R Morbidoni, and S Borsuk, and O Dellagostin, and I Marcipar
January 2003, Vaccine,
I Bontempi, and K Leal, and E Prochetto, and G Díaz, and G Cabrera, and A Bortolotti, and H R Morbidoni, and S Borsuk, and O Dellagostin, and I Marcipar
May 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
I Bontempi, and K Leal, and E Prochetto, and G Díaz, and G Cabrera, and A Bortolotti, and H R Morbidoni, and S Borsuk, and O Dellagostin, and I Marcipar
June 2017, Scandinavian journal of immunology,
I Bontempi, and K Leal, and E Prochetto, and G Díaz, and G Cabrera, and A Bortolotti, and H R Morbidoni, and S Borsuk, and O Dellagostin, and I Marcipar
November 2013, Parasitology research,
I Bontempi, and K Leal, and E Prochetto, and G Díaz, and G Cabrera, and A Bortolotti, and H R Morbidoni, and S Borsuk, and O Dellagostin, and I Marcipar
August 2009, Infection and immunity,
I Bontempi, and K Leal, and E Prochetto, and G Díaz, and G Cabrera, and A Bortolotti, and H R Morbidoni, and S Borsuk, and O Dellagostin, and I Marcipar
May 2006, Emerging infectious diseases,
I Bontempi, and K Leal, and E Prochetto, and G Díaz, and G Cabrera, and A Bortolotti, and H R Morbidoni, and S Borsuk, and O Dellagostin, and I Marcipar
September 2006, Iranian journal of allergy, asthma, and immunology,
I Bontempi, and K Leal, and E Prochetto, and G Díaz, and G Cabrera, and A Bortolotti, and H R Morbidoni, and S Borsuk, and O Dellagostin, and I Marcipar
February 2011, Fish & shellfish immunology,
I Bontempi, and K Leal, and E Prochetto, and G Díaz, and G Cabrera, and A Bortolotti, and H R Morbidoni, and S Borsuk, and O Dellagostin, and I Marcipar
December 2006, Journal of leukocyte biology,
Copied contents to your clipboard!